Richard Burrell’s Post

View profile for Richard Burrell, graphic

Clinical Pharmacology, First in Human, Proof of Mechanism, Proof of Concept and Bioanalysis

A co-located Phase I unit and bioanalytical lab is a major Celerion asset. This affords tremendous opportunities for FIH/Phase I studies requiring fast processing/analysis of samples. Studies employing time critical Flow and/or EliSpot assays are standout beneficiaries. It can also help reduce dose escalation timelines if PK or other data is needed - no shipping time to consider.

To view or add a comment, sign in

Explore topics